{"filing":{"accession_number":"0001193125-26-357185","cik":"0001515673","ticker":"RARE","company_name":"Ultragenyx Pharmaceutical Inc.","form":"8-K","filing_date":"2026-08-19","report_date":"2026-08-19","primary_document":"rare-20260819.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526357185/rare-20260819.htm"},"events":[{"id":28618,"run_id":26186,"accession_number":"0001193125-26-357185","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Ultragenyx announced FDA accelerated approval for GENGLYCOS (DTX401) for glycogen storage disease type Ia, a significant regulatory and commercial milestone for the company's pipeline. This is a material operational/strategic event—the approval of a novel gene therapy product—that does not fit the specific categories of earnings release, M\u0026A, or other named event types. The disclosure includes clinical trial data supporting the approval and post-marketing study commitments, indicating a major product advancement that would affect investor assessment of the company's prospects.","company_name":"Ultragenyx Pharmaceutical Inc.","ticker":"RARE","filing_date":"2026-08-19","form":"8-K","submitted_at":null,"items":[{"id":30619,"accession_number":"0001193125-26-357185","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Ultragenyx announced FDA accelerated approval for GENGLYCOS (DTX401) for glycogen storage disease type Ia, a significant regulatory and commercial milestone for the company's pipeline. This is a material operational/strategic event—the approval of a novel gene therapy product—that does not fit the specific categories of earnings release, M\u0026A, or other named event types. The disclosure includes clinical trial data supporting the approval and post-marketing study commitments, indicating a major product advancement that would affect investor assessment of the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T21:25:40.118675+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30619,"accession_number":"0001193125-26-357185","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Ultragenyx announced FDA accelerated approval for GENGLYCOS (DTX401) for glycogen storage disease type Ia, a significant regulatory and commercial milestone for the company's pipeline. This is a material operational/strategic event—the approval of a novel gene therapy product—that does not fit the specific categories of earnings release, M\u0026A, or other named event types. The disclosure includes clinical trial data supporting the approval and post-marketing study commitments, indicating a major product advancement that would affect investor assessment of the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T21:25:40.118675+00:00","company_name":"Ultragenyx Pharmaceutical Inc.","ticker":"RARE","filing_date":"2026-08-19"}]}